See the DrugPatentWatch profile for cosentyx

Based on the information provided, there are no specific concerns regarding the impact of vaccines on the effectiveness or safety of Cosentyx (secukinumab). Cosentyx is a medication used to treat several conditions, including plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis [1]. It is a monoclonal antibody that works by blocking the action of interleukin-17A, a protein involved in inflammation [1].

When it comes to vaccines, the Centers for Disease Control and Prevention (CDC) recommends that individuals on biologic therapies like Cosentyx follow the same vaccination guidelines as those not taking these medications [2]. However, live vaccines may not be recommended for people taking certain biologic drugs, including Cosentyx [2]. It is essential to consult with a healthcare provider to discuss vaccination plans and any potential risks or interactions [2].

It is also worth noting that, according to DrugPatentWatch.com, Cosentyx's primary patents are set to expire in 2024 and 2025 [3]. This information might be relevant for patients and healthcare providers when considering the long-term use and cost of Cosentyx.

In summary, there are no known specific concerns regarding the impact of vaccines on Cosentyx. However, it is always crucial to consult with a healthcare provider when considering vaccinations and medications.

Sources:

1. Cosentyx (secukinumab) Injection, for Subcutaneous Use [Prescribing Information]. Novartis Pharmaceuticals Corporation; 2021. Available from: <https://www.novartis.us/sites/www.novartis.us/files/cosentyx.pdf>.
2. Vaccinations for adults with weakened immune systems. Centers for Disease Control and Prevention. <https://www.cdc.gov/vaccines/adults/rec-vac/people-with-weakened-immune-systems.html>.
3. Secukinumab (Cosentyx). DrugPatentWatch.com. <https://www.drugpatentwatch.com/drugs/secukinumab>.